Chest[journal] 检索结果

341. Plasminogen: The Not-as-Obvious But Obvious Choice for Lytic Therapy.

作者: Paul Y Kim.
来源: Chest. 2025年167卷1期6-8页

342. Are Statistical Tests Really Needed to Compare Training and Validation Sets for Prediction Model Development and Evaluation?

作者: Yuxuan Jin.;Mithat Gönen.;Michael W Kattan.
来源: Chest. 2025年167卷1期40-41页

343. Use of β-Blockers in COPD: The Long and Winding Road.

作者: Brian J Lipworth.;Graham Devereux.
来源: Chest. 2025年167卷1期37-39页

344. Beyond Bronchodilation and Airway Inflammation: Mucus Plugs as a Therapeutic Target in COPD.

作者: Alejandro A Diaz.
来源: Chest. 2025年167卷1期34-36页

345. Rebuttal From Dr Jones.

作者: Barbara E Jones.
来源: Chest. 2025年167卷1期32-33页

346. Rebuttal From Dr Pickens.

作者: Chiagozie Pickens.
来源: Chest. 2025年167卷1期31-32页

347. Blurred Lines on the Dysbiosis Spectrum: Pneumocystis Colonization vs Infection by Metagenomics.

作者: Georgios D Kitsios.;Alison Morris.
来源: Chest. 2025年167卷1期3-5页

348. Corrigendum to: Pardeshi P, Mave V, Gaikwad S, Kadam D, Barthwal M, Gupte N, Atre S, Deshmukh S, Golub JE, Gupte A. Chest. 2024;165(2):278-287.

来源: Chest. 2025年167卷1期296页

349. COUNTERPOINT: Should Multiplex Molecular Panels Be Performed on All Patients With Community Acquired Pneumonia? No.

作者: Barbara E Jones.
来源: Chest. 2025年167卷1期27-31页

350. POINT: Should Multiplex Molecular Panels Be Performed on All Patients With Community Acquired Pneumonia? Yes.

作者: Chiagozie Pickens.
来源: Chest. 2025年167卷1期24-27页

351. Attic of Sorrow.

作者: Charles A Read.
来源: Chest. 2025年167卷1期222-223页

352. Infections and Lung Cancer: An Opportunity to Identify High-Risk Individuals Beyond Smoking?

作者: Dominique S Michaud.
来源: Chest. 2025年167卷1期21-23页

353. Decisions, Decisions: Are Current Shared Decision-Making Tools for Lung Cancer Screening Too Complicated?

作者: Neelima Navuluri.;Scott Shofer.
来源: Chest. 2025年167卷1期19-20页

354. Phosphodiesterase-5 Inhibitors Show Promise in Improving Survival for Patients With COPD Pulmonary Hypertension: One Step Further But There Is Still a Long Way to Go.

作者: Ari Chaouat.;Simon Valentin.;Yochai Adir.
来源: Chest. 2025年167卷1期16-18页

355. One Step Closer to Personalized Management of Neuromuscular Respiratory Failure.

作者: Thomas H Fox.;Philip J Choi.
来源: Chest. 2025年167卷1期14-15页

356. Extubation Failure Among Patients With Obesity.

作者: Amit Kansal.;Maurizio Cecconi.
来源: Chest. 2025年167卷1期11-13页

357. Weighing the Options: New Insights and Ongoing Challenges in Asthma With Obesity.

作者: Matthew S McCravy.;Jennifer L Ingram.;Loretta G Que.
来源: Chest. 2025年167卷1期1-2页

358. Demystifying Volume Status: An Ultrasound-Guided Physiologic Framework.

作者: Juliana Yl Kan.;Shane Arishenkoff.;Katie Wiskar.
来源: Chest. 2025年167卷6期1667-1683页

Accurate assessment of a patient's volume status is crucial in many conditions, informing decisions on fluid prescribing, vasoactive agents, and decongestive therapies. Determining a patient's volume status is challenging because of limitations in examination and investigations and the complexities of fluid homeostasis in disease states. Point-of-care ultrasound (POCUS) is useful in assessing hemodynamic parameters related to volume status, fluid responsiveness, and fluid tolerance. It requires understanding several physiologic concepts to interpret and integrate POCUS findings accurately into volume-related clinical decision-making.

359. Association of Lung Function With Visceral Adiposity and Skeletal Muscle Mass Considering Myosteatosis.

作者: Young Ju Jung.;Min Jung Lee.;Eun Hee Kim.;Sung-Jin Bae.;Hong-Kyu Kim.
来源: Chest. 2025年167卷6期1714-1726页

Changes in body composition, including loss of muscle mass and obesity, adversely affect lung function.

360. Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.

作者: Peter J Leary.;Samuel G Rayner.;Kelley R H Branch.;Laurie Hogl.;Nancy M Liston.;Lia M Barros.;Jessi Prout.;Stephanie Nolley.;Jonathan Buber.;David D Ralph.;Jeffrey L Probstfield.
来源: Chest. 2025年168卷1期189-199页

Adaptation of the right ventricle is a key determinant of outcomes in pulmonary arterial hypertension (PAH). Despite a compelling rationale to develop targeted therapies for the right ventricle in PAH, no such treatments exist. H2-receptor antagonism is a potential myocardial-focused paradigm in heart failure.

结果排序

文献格式

出版时间

出版类型

出版语言